tbuckley/cabot-search huggingface dataset:
Dyadic coping and mental health in couples: A systematic review
Authors: Selina A. Landolt, Katharina Weitkamp, Michelle Roth, Natalie M. Sisson, Guy Bodenmann
Journal: Clinical Psychology Review (2023)

Globally, one out of three people suffer from a mental health issue during their lifetime. In romantic relationships, impaired mental health does not only affect the individual but also their partner and therefore needs to be coped with dyadically. In this systematic review, we summarize research examining dyadic coping (DC) in the context of mental health and individual and relational outcomes. We searched for peer-reviewed articles published between January 1990 and April 2023 on PsycInfo, Medline, and PSYNDEX on DC and mental health within romantic relationships. A total of 60 qualitative, quantitative, and intervention studies met the inclusion criteria, reporting on 16,394 individuals and 4,945 dyads. To synthesize the studies, we used a narrative synthesis approach. Overall, stress expression and positive DC yielded beneficial individual and relational outcomes, whereas, for negative DC, the opposite was true. Results differed between mental health clusters and context played an important role (e.g., symptom severity, life phase). Due to the great diversity of studies and variables, further research should focus on understudied mental health clusters (e.g., anxiety disorders). Clinicians are advised to view mental health issues as a dyadic rather than an individual phenomenon ("we-disease") and develop tailored couple-centered interventions.
Progresses in biomarkers for cancer immunotherapy
Authors: Xuwen Lin, Chenyu Zong, Zhihan Zhang, Weiyi Fang, Ping Xu
Journal: MedComm (2023)

Currently, checkpoint inhibitor-based immunotherapy has emerged as prevailing treatment modality for diverse cancers. However, immunotherapy as a first-line therapy has not consistently yielded durable responses. Moreover, the risk of immune-related adverse events increases with combination regimens. Thus, the development of predictive biomarkers is needed to optimize individuals benefit, minimize risk of toxicities, and guide combination approaches. The greatest focus has been on tumor programmed cell death-ligand 1 (PD-L1), microsatellite instability (MSI), and tumor mutational burden (TMB). However, there remains a subject of debate due to thresholds variability and significant heterogeneity. Major unmet challenges in immunotherapy are the discovery and validation of predictive biomarkers. Here, we show the status of tumor PD-L1, MSI, TMB, and emerging data on novel biomarker strategies with oncogenic signaling and epigenetic regulation. Considering the exploration of peripheral and intestinal immunity has served as noninvasive alternative in predicting immunotherapy, this review also summarizes current data in systemic immunity, encompassing solute PD-L1 and TMB, circulating tumor DNA and infiltrating lymphocytes, routine emerging inflammatory markers and cytokines, as well as gut microbiota. This review provides up-to-date information on the evolving field of currently available biomarkers in predicting immunotherapy. Future exploration of novel biomarkers is warranted.
Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic review
Authors: Nawar Tarafdar, Muskaan Sachdeva, Iryna Savinova, Yuliya Lytvyn, Khalad Maliyar, Jorge R. Georgakopoulos, Asfandyar Mufti, Jensen Yeung
Journal: Journal of the American Academy of Dermatology (2023)
News beyond our pages
Authors: Marc E. Rothenberg, Jean Bousquet
Journal: Journal of Allergy and Clinical Immunology (2023)

Lockhart et al (J Exp Med 2023;220:e20221816; https://doi.org/10.1084/jem.20221816) identified an important tolerogenic role for dietary protein in C57BL/6J mice. Food proteins ingested during homeostasis induced polyclonal antigen-specific expansion of CD4+ T cells in the intestinal epithelium with enriched cytotoxic gene expression. Notably, this process was enhanced by commensal bacteria. Furthermore, active tolerance was associated with influx of antigen-experienced regulatory T cells whereas polyclonal expansion of proinflammatory CD4+ T was observed in the contexts of food allergy.
Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases
Authors: Cameron Durfee, Nuri Alpay Temiz, Rena Levin-Klein, Prokopios P. Argyris, Lene Alsøe, Sergio Carracedo, Alicia Alonso de la Vega, Joshua Proehl, Anna M. Holzhauer, Zachary J. Seeman, Xingyu Liu, Yu-Hsiu T. Lin, Rachel I. Vogel, Rocio Sotillo, Hilde Nilsen, Reuben S. Harris
Journal: Cell Reports Medicine (2023)

The antiviral DNA cytosine deaminase APOBEC3B has been implicated as a source of mutation in many cancers. However, despite years of work, a causal relationship has yet to be established in vivo. Here, we report a murine model that expresses tumor-like levels of human APOBEC3B. Animals expressing full-body APOBEC3B appear to develop normally. However, adult males manifest infertility, and older animals of both sexes show accelerated rates of carcinogenesis, visual and molecular tumor heterogeneity, and metastasis. Both primary and metastatic tumors exhibit increased frequencies of C-to-T mutations in TC dinucleotide motifs consistent with the established biochemical activity of APOBEC3B. Enrichment for APOBEC3B-attributable single base substitution mutations also associates with elevated levels of insertion-deletion mutations and structural variations. APOBEC3B catalytic activity is required for all of these phenotypes. Together, these studies provide a cause-and-effect demonstration that human APOBEC3B is capable of driving both tumor initiation and evolution in vivo.
EVI1-mediated Programming of Normal and Malignant Hematopoiesis
Authors: Susanne Lux, Michael D. Milsom
Journal: HemaSphere (2023)

Ecotropic viral integration site 1 (EVI1 ), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context-dependent manner and regulates transcription and chromatin remodeling, thereby influencing the proliferation, differentiation, and survival of cells. Interestingly, it can act both as a transcriptional activator as well as a transcriptional repressor. EVI1 is expressed, and fulfills important functions, during the development of different tissues, including the nervous system and hematopoiesis, demonstrating a rigid spatial and temporal expression pattern. However, EVI1 is regularly overexpressed in a variety of cancer entities, including epithelial cancers such as ovarian and pancreatic cancer, as well as in hematologic malignancies like myeloid leukemias. Importantly, EVI1 overexpression is generally associated with a very poor clinical outcome and therapy-resistance. Thus, EVI1 is an interesting candidate to study to improve the prognosis and treatment of high-risk patients with “EVI1 high ” hematopoietic malignancies.
Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer
Authors: YongHwan Kim, Hyein Ju, Seung-Yeon Yoo, Jinahn Jeong, Jinbeom Heo, Seungun Lee, Ja-Min Park, Sun Young Yoon, Se Un Jeong, Jinyoung Lee, HongDuck Yun, Chae-Min Ryu, Jinah Lee, Yun Ji Nam, Hyungu Kwon, Jaekyoung Son, Gowun Jeong, Ji-Hye Oh, Chang Ohk Sung, Eui Man Jeong, Jaehoon An, Sungho Won, Bumsik Hong, Jae Lyun Lee, Yong Mee Cho, Dong-Myung Shin
Journal: Cell Reports Medicine (2023)

Radical cystectomy with preoperative cisplatin-based neoadjuvant chemotherapy (NAC) is the standard care for muscle-invasive bladder cancers (MIBCs). However, the complete response rate to this modality remains relatively low, and current clinicopathologic and molecular classifications are inadequate to predict NAC response in patients with MIBC. Here, we demonstrate that dysregulation of the glutathione (GSH) pathway is fundamental for MIBC NAC resistance. Comprehensive analysis of the multicohort transcriptomes reveals that GSH metabolism and immune-response genes are enriched in NAC-resistant and NAC-sensitive MIBCs, respectively. A machine-learning-based tumor/stroma classifier is applied for high-throughput digitalized immunohistochemistry analysis, finding that GSH dynamics proteins, including glutaminase-1, are associated with NAC resistance. GSH dynamics is activated in cisplatin-resistant MIBC cells, and combination treatment with a GSH dynamics modulator and cisplatin significantly suppresses tumor growth in an orthotopic xenograft animal model. Collectively, these findings demonstrate the predictive and therapeutic values of GSH dynamics in determining the NAC response in MIBCs.
A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe
Authors: Nasreen Hassoun-Kheir, Mariana Guedes, Marie-Therese Ngo Nsoga, Lorenzo Argante, Fabiana Arieti, Beryl P. Gladstone, Rhys Kingston, Nichola R. Naylor, Maria D. Pezzani, Koen B. Pouwels, Julie V. Robotham, Jesús Rodríguez-Baño, Evelina Tacconelli, Venanzio Vella, Stephan Harbarth, Marlieke E.A. de Kraker, Benedetta Barana, Eva Cappelli, Maria Elena De Rui, Radwa A. El-Abasiri, Liliana Galia, Jeroen Geurtsen, Jorly Mejia, Andrea Palladino, Alen Piljic, Nithya Babu Rajendran, Eduardo Reyna-Villasmil, Johannes E. Schmidt
Journal: Clinical Microbiology and Infection (2023)

Antimicrobial resistance is a global threat, which requires novel intervention strategies, for which priority pathogens and settings need to be determined.
Polyphenol-mediated sandwich-like coating promotes endothelialization and vascular healing
Authors: Huining Wan, Yanyan Li, Yumei Qin, Yongqi An, Hui Yan, Xiyu Liu, Hao Zhang, Cheng Hu, Linhua Li, Daihua Fu, Yuan Yang, Yan Dai, Rifang Luo, Li Yang, Bo Zhang, Yunbing Wang
Journal: Biomaterials (2023)
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
Authors: Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, Marina Magrey, Walter P Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Carmen Fleurinck, Alicia M Ellis, Thomas Vaux, Julie Shepherd-Smith, Alexander Marten, Lianne S Gensler
Journal: Annals of the Rheumatic Diseases (2023)

Objectives Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated superior efficacy versus placebo in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA) at Week 16. Here, the objective is to report the efficacy and safety of BKZ at Week 52. Methods BE MOBILE 1 (nr-axSpA; NCT03928704 ) and BE MOBILE 2 (r-axSpA; NCT03928743 ) comprised a 16-week, double-blind, placebo-controlled period, then a 36-week maintenance period. From Week 16, all patients received subcutaneous BKZ 160 mg every 4 weeks. Results Improvements versus placebo in Assessment of SpondyloArthritis International Society ≥40% response (primary endpoint), Ankylosing Spondylitis Disease Activity Score, high-sensitivity C-reactive protein levels and MRI inflammation of the sacroiliac joints/spine at Week 16 were sustained to Week 52 in BKZ-randomised patients. At Week 52, responses of patients switching from placebo to BKZ at Week 16 were comparable to BKZ-randomised patients. At Week 52, ≥1 treatment-emergent adverse events (TEAEs) were reported in 183 (75.0%) and 249 (75.5%) patients with nr-axSpA and r-axSpA, respectively. Serious TEAEs occurred in 9 (3.7%) patients with nr-axSpA and 20 (6.1%) patients with r-axSpA. Oral candidiasis was the most frequent fungal infection (nr-axSpA: 18 (7.4%); r-axSpA: 20 (6.1%)). Uveitis occurred in three (1.2%) and seven (2.1%) patients with nr-axSpA and r-axSpA, and inflammatory bowel disease in two (0.8%) and three (0.9%). Conclusions At Week 52, dual inhibition of IL-17A and IL-17F with BKZ resulted in sustained efficacy across the axSpA spectrum; the safety profile was consistent with the known safety of BKZ. Trial registration number NCT03928704 ; NCT03928743 .
Ambient PM2.5 Exposure and Bone Homeostasis: Analysis of UK Biobank Data and Experimental Studies in Mice and <i>in Vitro</i>
Authors: Qinwen Ge, Sijia Yang, Yu Qian, Jiali Chen, Wenhua Yuan, Sanduo Li, Pinger Wang, Ran Li, Lu Zhang, Guobo Chen, Haidong Kan, Sanjay Rajagopalan, Qinghua Sun, Hou-Feng Zheng, Hongting Jin, Cuiqing Liu
Journal: Environmental Health Perspectives (2023)

Background: Previous evidence has identified exposure to fine ambient particulate matter (PM2.5) as a leading risk factor for adverse health outcomes. However, to date, only a few studies have examined the potential association between long-term exposure to PM2.5 and bone homeostasis. Objective: We sought to examine the relationship between long-term PM2.5 exposure and bone health and explore its potential mechanism. Methods: This research included both observational and experimental studies. First, based on human data from UK Biobank, linear regression was used to explore the associations between long-term exposure to PM2.5 (i.e., annual average PM2.5 concentration for 2010) and bone mineral density [BMD; i.e., heel BMD (n=37,440) and femur neck and lumbar spine BMD (n=29,766)], which were measured during 2014–2020. For the experimental animal study, C57BL/6 male mice were assigned to ambient PM2.5 or filtered air for 6 months via a whole-body exposure system. Micro-computed tomography analyses were applied to measure BMD and bone microstructures. Biomarkers for bone turnover and inflammation were examined with histological staining, immunohistochemistry staining, and enzyme-linked immunosorbent assay. We also performed tartrate-resistant acid phosphatase (TRAP) staining and bone resorption assay to determine the effect of PM2.5 exposure on osteoclast activity in vitro. In addition, the potential downstream regulators were assessed by real-time polymerase chain reaction and western blot. Results: We observed that long-term exposure to PM2.5 was significantly associated with lower BMD at different anatomical sites, according to the analysis of UK Biobank data. In experimental study, mice exposed long-term to PM2.5 exhibited excessive osteoclastogenesis, dysregulated osteogenesis, higher tumor necrosis factor-alpha (TNF-α) expression, and shorter femur length than control mice, but they demonstrated no significant differences in femur structure or BMD. In vitro, cells stimulated with conditional medium of PM2.5-stimulated macrophages had aberrant osteoclastogenesis and differences in the protein/mRNA expression of members of the TNF-α/Traf6/c-Fos pathway, which could be partially rescued by TNF-α inhibition. Discussion: Our prospective observational evidence suggested that long-term exposure to PM2.5 is associated with lower BMD and further experimental results demonstrated exposure to PM2.5 could disrupt bone homeostasis, which may be mediated by inflammation-induced osteoclastogenesis. https://doi.org/10.1289/EHP11646
Multimodal Imaging‐Guided Photoimmunotherapy of Pancreatic Cancer by Organosilica Nanomedicine
Authors: Huifeng Zhang, Kun Chen, Kai Guo, Jun Tao, Lina Song, Shuai Ren, Yatong Zhao, Zhaogang Teng, Wenli Qiu, Zhongqiu Wang
Journal: Advanced Healthcare Materials (2023)

Abstract Immune checkpoint blockade (ICB) treatments have contributed to substantial clinical progress. However, challenges persist, including inefficient drug delivery and penetration into deep tumor areas, inadequate response to ICB treatments, and potential risk of inflammation due to over‐activation of immune cells and uncontrolled release of cytokines following immunotherapy. In response, this study, for the first time, presents a multimodal imaging‐guided organosilica nanomedicine (DCCGP) for photoimmunotherapy of pancreatic cancer. The novel DCCGP nanoplatform integrates fluorescence, magnetic resonance, and real‐time infrared photothermal imaging, thereby enhancing diagnostic precision and treatment efficacy for pancreatic cancer. In addition, the incorporated copper sulfide nanoparticles (CuS NPs) lead to improved tumor penetration and provide external regulation of immunotherapy via photothermal stimulation. The synergistic immunotherapy effect is realized through the photothermal behavior of CuS NPs, inducing immunogenic cell death and relieving the immunosuppressive tumor microenvironment. Coupling photothermal stimulation with αPD‐L1‐induced ICB, the platform amplifies the clearance efficiency of tumor cells, achieving an optimized synergistic photoimmunotherapy effect. This study offers a promising strategy for the clinical application of ICB‐based combined immunotherapy and presents valuable insights for applications of organosilica in precise tumor immunotherapy and theranostics.
Neutralization against emerging Omicron subvariants after SARS-CoV-2 reinfection
Authors: Shen Tian, Ti Liu, Xin-Jing Zhao, Xiao-Lin Liu, Xin-Lou Li, Kai-Ge Du, Li-Qun Fang, Zeng-Qiang Kou, Yue-Hong Wei, Guo-Lin Wang
Journal: Journal of Infection (2023)
Exposure to Particulate Matter Air Pollution and Age of Menarche in a Nationwide Cohort of U.S. Girls
Authors: Robert B. Hood, Jaime E. Hart, Francine Laden, Bernard Rosner, Jorge E. Chavarro, Audrey J. Gaskins
Journal: Environmental Health Perspectives (2023)

Background: It remains unclear whether in utero and childhood exposure to air pollution affects pubertal development, particularly age of menarche in girls. Objective: The aim of this study was to determine whether residential ambient particulate matter (PM) exposure in utero and during childhood is associated with age of menarche. Methods: We studied 5,201 girls in the Growing Up Today Study 2 (2004–present) who were 10–17 y of age at enrollment (47.7% premenarchal; 52.3% postmenarchal). Exposure to three size fractions of PM [fine PM with aerodynamic diameter ≤2.5μm (PM2.5), PM with aerodynamic diameters between 2.5μm and 10μm (PM2.5–10), and PM with aerodynamic diameter 10μm (PM10)] was assigned based on maternal residential address, updated every 2 y, using nationwide spatiotemporal models. We estimated average PM exposure in utero, and time-varying windows: annual average exposure in the prior 1 and 2 y and cumulative average from birth. Age of menarche was self-reported on three surveys administered in 2004, 2006, and 2008. We calculated hazard ratios (HR) for menarche for an interquartile range (IQR) increase in PM exposure using Cox proportional hazard models adjusting for potential confounders. Results: Girls attained menarche at 12.3 y of age on average. In the adjusted model, higher residential exposure to ambient PM2.5 during all time windows was associated with earlier age of menarche. The HRs of menarche for each IQR (4 μg/m3) increase in exposure to PM2.5 during the in utero period, 1 y prior to menarche, and throughout childhood were 1.03 [95% confidence interval (CI): 1.00, 1.06], 1.06 (95% CI: 1.02, 1.10) and 1.06 (95% CI: 1.02, 1.10), respectively. Effect estimates for PM10 exposure were similar, albeit attenuated, for all time windows. PM2.5–10 exposure was not associated with age of menarche. Discussion: Among a large, nationwide, prospective cohort of U.S. girls, higher exposure to PM2.5 and PM10 in utero and throughout childhood was associated with an earlier age of menarche. Our results suggest that PM2.5 and PM10 may have endocrine-disrupting properties that could lead to altered timing of menarche. https://doi.org/10.1289/EHP12110
Human genetics and molecular genomics of Chiari malformation type 1
Authors: Kedous Y. Mekbib, William Muñoz, Garrett Allington, Stephen McGee, Neel H. Mehta, John P. Shofi, Carla Fortes, Hao Thi Le, Carol Nelson-Williams, Pranav Nanda, Evan Dennis, Adam J. Kundishora, Arjun Khanna, Hannah Smith, Jack Ocken, Ana B.W. Greenberg, Rui Wu, Andres Moreno-De-Luca, Tyrone DeSpenza, Shujuan Zhao, Arnaud Marlier, Sheng Chih Jin, Seth L. Alper, William E. Butler, Kristopher T. Kahle
Journal: Trends in Molecular Medicine (2023)
Backgrounds and the evolution of visual signals
Authors: Eleanor M. Caves, Alexander L. Davis, Stephen Nowicki, Sönke Johnsen
Journal: Trends in Ecology & Evolution (2023)

Color signals which mediate behavioral interactions across taxa and contexts are often thought of as color 'patches' – parts of an animal that appear colorful compared to other parts of that animal. Color patches, however, cannot be considered in isolation because how a color is perceived depends on its visual background. This is of special relevance to the function and evolution of signals because backgrounds give rise to a fundamental tradeoff between color signal detectability and discriminability: as its contrast with the background increases, a color patch becomes more detectable, but discriminating variation in that color becomes more difficult. Thus, the signal function of color patches can only be fully understood by considering patch and background together as an integrated whole.
Type 2 Diabetes — Controlling the Epidemic, Episode 3: Fostering Patient Engagement and Lifestyle Modifications
Authors: E. Dale Abel, Julie R. Ingelfinger, Suyanna Linhales Barker, Dinora Lopez, Mirna Mejia, Monica Peek, Jane E.B. Reusch, Clifford J. Rosen
Journal: New England Journal of Medicine (2023)

In this third episode of "Type 2 Diabetes — Controlling the Epidemic," a four-part Double Take video miniseries from the New England Journal of Medicine, Drs. Jane E.B. Reusch (University of Colorado), E. Dale Abel (UCLA), and Monica Peek (University of Chicago) discuss the importance of lifestyle modifications as the foundation of diabetes management. The experts outline ways to partner with patients to improve their nutrition and increase physical activity.
Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints
Authors: Rebecca T. Hahn, Matthew K. Lawlor, Charles J. Davidson, Vinay Badhwar, Anna Sannino, Ernest Spitzer, Philipp Lurz, Brian R. Lindman, Yan Topilsky, Suzanne J. Baron, Scott Chadderdon, Omar K. Khalique, Gilbert H.L. Tang, Maurizio Taramasso, Paul A. Grayburn, Luigi Badano, Jonathon Leipsic, JoAnn Lindenfeld, Stephan Windecker, Sreekanth Vemulapalli, Bjorn Redfors, Maria C. Alu, David J. Cohen, Josep Rodés-Cabau, Gorav Ailawadi, Michael Mack, Ori Ben-Yehuda, Martin B. Leon, Jörg Hausleiter, Suzanne Arnold, Vinayak Bapat, Natalia Berry, Philipp Blanke, Daniel Burkhoff, Megan Coylewright, Neal Duggal, Benjamin Galper, Isaac George, Mayra Guerrero, Nadira Hamid, Vikrant Jagadeesan, Susheel Kodali, Mitch Krucoff, Roberto Lang, Mahesh Madhavan, Vallerie McLaughin, Roxana Mehran, Francois Philippon, Sanjum S. Sethi, Matheus Simonato, Robert Smith, Nishtha Sodhi, John Spertus, Thomas J. Stocker, Gregg Stone
Journal: Journal of the American College of Cardiology (2023)

Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.